Frank Boehm
Frank J Boehm comes from a diverse background that includes a 12-year stint as a full-time rock/pop musician, and 17 years as a senior mechanical designer of dedicated robotic tooling for complex automated assembly systems. He has been further engaged as a nanotechnology consultant, technology scout, product designer, research associate, and academic writer/editor for several international corporations and university laboratories, and the author of four books.
Frank has been involved with nanotechnology (especially nanomedicine) since 1996 when he serendipitously encountered the concept of nanotechnology, in which he autodidactically trained himself. He passionately proceeded to evolve and textually articulate various advanced near-term and longer-term nanomedical concepts and designs with the aim of transforming them into real world applications for global benefit. Concomitantly, he corresponded with numerous nanotech/nanomed research scientists and thought leaders from across the globe and founded NanoApps Medical, Inc. (2009).
Upon recognizing the immense potential of nanomedicine to impart positive paradigm shifts across the medical domain, he was deeply motivated to write more extensively on the topic. This culminated in the authoring/publication of his first book, Nanomedical Device and Systems Design: Challenges, Possibilities, Visions (CRC Press, 2013). Subsequently, he authored/co-authored numerous book chapters and journal articles, including an in-depth paper entitled ‘Human Brain/Cloud Interface’ (Frontiers in Neuroscience, 2019), and co-founded NanoApps Athletics, Inc. in the same year.
Frank then set his focus on a far more expansive investigation into the possibilities of nanotechnology/nanomedicine coupled with AI/AGI/ASI and quantum computation via the simultaneous compilation of a set of three companion books (with multiple chapter contributors for each) that explore a trifecta of envisaged global-scale paradigm-shifting technology platforms: Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence (CRC Press, 2025), Molecular Manufacturing: The Future of Nanomedicine (CRC Press, 2025), and Nanomedical Brain/Cloud Interface: Explorations and Implications (IOP Publishing, 2025).
In 2024, together with Amanda Scott (CEO NanoApps Medical, Inc., Co-Founder Alias Group Creative) Frank initially began to explore the idea/possibility for the establishment of a nonprofit dedicated to the realization of the vision of Global Health Care Equivalency for the benefit of humanity.
Ernest Daddey
Ernest Daddey is an award-winning Materials Scientist, entrepreneur, and senior technology executive with more than 25 years of experience leading the commercialization of advanced engineering materials and manufacturing technologies. He has a proven record of transforming research-driven innovation into scalable, revenue-generating businesses, reducing technicaland market risk for investors and public funding partners.
Ernest specializes in the innovation-to-commercialization lifecycle, including applied R&D, product and process development, pilot manufacturing, quality systems (QMS), new product development and introduction (NPD/NPI), and global go-to-market execution. His work consistently delivers commercial traction, IP creation, capital attraction, and economic impact across multiple sectors including clean technology, advanced materials, digital sensing, energy, infrastructure, and industrial systems.
Ernest has held senior leadership and advisory roles including CEO, Chief Development Officer, Vice President of Technology Development, Chief Scientific Advisor, and CTO, supporting both startups and public companies. His experience spans Canada, the United States, Europe, the UK, Africa, and Japan, enabling effective execution across international supply chains, regulatory environments, and commercialization pathways.
As an inventor of six patents and multiple trademarks, Ernest strengthens project defensibility and long-term value creation. He is frequently engaged by companies and public-sector programs to de-risk technology development, accelerate time-to-market, and align innovation roadmaps with investor and government funding criteria. His leadership emphasizes capital efficiency, partnerships, and measurable outcomes, supporting sustainable growth and job creation.